Additional COVID-19 booster vaccination for those aged 18-49 years
IO_74adca50-5d5e-4a54-ae66-d95e52632c23
Letter to Chief Medical Officer. Regarding inclusion of additional cohorts of the population in the booster COVID-19 programme
IO_15f8130e-44e9-48dd-8f72-96695197ae3a
Letter to CMO re. Bivalent COVID-19 vaccine for Children aged 5-11 years
IO_12c4e08a-06f5-4d88-bc6e-291d9dcf966a
Letter to the Chief Medical Office. Regarding recommendations for Nuvaxovid COVID-19 vaccine (Novavax)
IO_eeee99c1-26d0-47d3-8ceb-adf229fd73e7
Letter to the Chief Medical Office. Regarding recommendations for the use of smallpox (vaccinia) vaccine as pre and post exposure prophylaxis against monkeypox
IO_19aeaa8a-902a-4bc0-b7bf-e2e741cc7f61
Medium term strategy for the COVID-19 vaccination programme: recommendations for second booster dose; future considerations
IO_b889cf70-67aa-48de-a8eb-8b00353fc548
Monkeypox vaccination
IO_710d7d80-7a37-4e20-8f21-2d9eba927c47
NIAC Letter to CMO re. Post vaccination observation period